Chemoradiotherapy for cervical cancer

European Journal of Cancer

Volumn 38, Issue 2, 2002, Pages 270-278

  Rose, P G ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cervix; Chemoradiotherapy; Cisplatin

Indexed keywords

CISPLATIN; HYDROXYUREA;

ACUTE TOXICITY; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 0036170561     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00352-5     Document Type: Article

References (76)

1. Global cancer statistics
2. Average years of life lost from cancer
3. The disproportionately lower cancer survival rate with increased incidence and mortality in minorities and underserved Americans
4. Locally advanced cervical cancer
5. Clinical dose-response curves of human malignant epithelial tumours
6. Advanced stage IIIB cancer of the cervix treatment by hyperthermia and radiation
7. Neutron therapy in cervical cancer: Results of a phase III RTOG study
8. A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer
9. High dose rate intracavitary brachytherapy for carcinoma of the cervix: The Madison system: I. Clinical and radiobiological considerations
10. The effect of treatment duration in the local control of cervix cancer
11. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies
12. Analysis of sites and causes of failure of irradiation in invasive squamous cell carcinoma of the intact uterine cervix
13. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group study
14. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: A randomized Radiation Therapy Oncology Group clinical trial
15. Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer: Results of a randomized Gynecologic Oncology Group study
16. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a phase III intergroup study
17. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group
18. Concomitant chemotherapy: Rational and clinical experience in patients with solid tumors
19. Essai randomisé de chimiothérapie initiale dans 151 carcinomes du col utérin localement étendus (T2b-N1, T3b, MO)
20. Neodjuvant bleomycin, ifosfamide and cisplatin in cervical cancer
21. A randomized trial of chemotherapy followed by pelvic radiation therapy in Stage IIIB carcinoma of the cervix
22. Neoadjuvant chemotherapy (CT) + radiotherapy vs radiotherapy alone in stage IIIB cervical carcinoma. Preliminary results
23. Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: A randomized study
24. Induction chemotherapy and radiotherapy of advanced cancer of the cervix: A pilot study and phase III randomized trial
25. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer
26. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A
27. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group)
28. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer
29. Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer
30. The hazard of accelerated tumor clonogen repopulation during radiotherapy
31. Hydroxyurea with irradiation for cervical carcinoma - A preliminary report
32. Hydroxyurea and radiation therapy in advanced cervical cancer
33. Hydroxyureas a radiation sensitizer in women with carcinoma of the uterine cervix
34. Hydroxyureas: A radiation potentiator in carcinoma of the uterine cervix: A randomized double-blind study
35. Hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation in surgically staged stage IIIB cervical cancer
36. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis
37. Hydroxyurea versus mosonidazole with radiation in cervical carcinoma: Long-term follow-up of a Gynecologic Oncology Group trial
38. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x-rays
39. Concurrent radiation, mitomycin C and 5-fluorouracil in poor prognosis carcinoma of cervix: Preliminary results of a phase I-II study
40. Concurrent chemoradiation in advanced cervical cancer
41. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer
42. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix. A Southwest Oncology Group study
43. A randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study
44. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines
45. A review of interactions between platinum coordination complexes and ionizing radiation: Implications for cancer therapy
46. Experimental studies on schedule dependence in the treatment of cancer with combinations of chemotherapy and radiotherapy
47. Curability of mouse L1210 Leukemia by combination 5-fluorouracil, cis-diaminedichloroplatnum 11 and low doses of gamma rays
48. Effect of cis-dichlorodiammine platinum II and X rays on mammalian cell survival
49. Effect of cisplatin resistance on cellular radiation response
50. 5-Fluorouracil, leucovorin, hydroxyurea and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: A clinical and pharmacologic study
51. Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: A phase I-II trial of the Gynecologic Oncology Group
52. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas
53. 1975 Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma
54. Radical hysterectomy for Stage 1B1 vs 1B2 carcinoma of the cervix: Does the new staging system predict morbidity and survival?
55. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study
56. The effect of treatment duration in the local control of cervix cancer
57. A clinical trial comparing concurrent cisplatin and radiation alone for locally advanced squamous cell carcinoma of the cervix carried out by the National Cancer Institute of Canada Clinical Trials Group
58. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix
59. Chemoradiation and adjuvant chemotherapy in cervical cancer
60. Cis-diamminedichloroplatinum II based combination chemotherapy for the control of extensive paraaortic lymph node metastasis in cervical cancer
61. Concurrent chemotherapy and radiation for locally advanced cervical cancer: The new standard of care
62. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group
63. The morbidity and utility of a periaortic radiotherapy in cervical carcinoma
64. Five-year survival (NED) in patients with biopsy confirmed aortic node metastasis from cervical carcinoma
65. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive paraaortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10
66. Cervical carcinoma metastatic to the para-aortic nodes: Extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy therapy: A Gynecologic Oncology Group study
67. Extended field radiation and cisplatin for stage IIB and IIIB cervical carcinoma
68. Carboplatin as a radiation sensitizer in locally advanced cervical cancer: A pilot study
69. Paclitaxel: A radiation sensitizer of human cervical cancer cells
70. The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine
71. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts
72. Tirapazamine: Hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay
73. Campthothecin radiation sensitization: Mechanisms, schedules, and timing